AAPL   327.87 (+1.72%)
MSFT   185.57 (+1.45%)
FB   229.84 (+1.57%)
GOOGL   1,429.46 (+1.07%)
AMZN   2,467.62 (+0.29%)
NVDA   353.39 (+0.78%)
CGC   16.94 (+1.86%)
BABA   219.71 (+0.77%)
MU   53.74 (+4.92%)
TSLA   875.18 (+1.25%)
AMD   52.40 (-0.44%)
T   32.87 (+3.37%)
ACB   13.93 (-2.11%)
F   7.29 (+10.96%)
GILD   77.10 (-0.57%)
DIS   126.76 (+2.48%)
NFLX   414.38 (+0.01%)
BAC   28.42 (+6.12%)
BA   214.19 (+16.22%)
AAPL   327.87 (+1.72%)
MSFT   185.57 (+1.45%)
FB   229.84 (+1.57%)
GOOGL   1,429.46 (+1.07%)
AMZN   2,467.62 (+0.29%)
NVDA   353.39 (+0.78%)
CGC   16.94 (+1.86%)
BABA   219.71 (+0.77%)
MU   53.74 (+4.92%)
TSLA   875.18 (+1.25%)
AMD   52.40 (-0.44%)
T   32.87 (+3.37%)
ACB   13.93 (-2.11%)
F   7.29 (+10.96%)
GILD   77.10 (-0.57%)
DIS   126.76 (+2.48%)
NFLX   414.38 (+0.01%)
BAC   28.42 (+6.12%)
BA   214.19 (+16.22%)
AAPL   327.87 (+1.72%)
MSFT   185.57 (+1.45%)
FB   229.84 (+1.57%)
GOOGL   1,429.46 (+1.07%)
AMZN   2,467.62 (+0.29%)
NVDA   353.39 (+0.78%)
CGC   16.94 (+1.86%)
BABA   219.71 (+0.77%)
MU   53.74 (+4.92%)
TSLA   875.18 (+1.25%)
AMD   52.40 (-0.44%)
T   32.87 (+3.37%)
ACB   13.93 (-2.11%)
F   7.29 (+10.96%)
GILD   77.10 (-0.57%)
DIS   126.76 (+2.48%)
NFLX   414.38 (+0.01%)
BAC   28.42 (+6.12%)
BA   214.19 (+16.22%)
AAPL   327.87 (+1.72%)
MSFT   185.57 (+1.45%)
FB   229.84 (+1.57%)
GOOGL   1,429.46 (+1.07%)
AMZN   2,467.62 (+0.29%)
NVDA   353.39 (+0.78%)
CGC   16.94 (+1.86%)
BABA   219.71 (+0.77%)
MU   53.74 (+4.92%)
TSLA   875.18 (+1.25%)
AMD   52.40 (-0.44%)
T   32.87 (+3.37%)
ACB   13.93 (-2.11%)
F   7.29 (+10.96%)
GILD   77.10 (-0.57%)
DIS   126.76 (+2.48%)
NFLX   414.38 (+0.01%)
BAC   28.42 (+6.12%)
BA   214.19 (+16.22%)
Log in

NASDAQ:AVXLAnavex Life Sciences Stock Price, Forecast & News

$3.99
+0.08 (+2.05 %)
(As of 06/5/2020 11:13 AM ET)
Add
Compare
Today's Range
$3.93
Now: $3.99
$4.15
50-Day Range
$3.13
MA: $3.63
$4.24
52-Week Range
$2.20
Now: $3.99
$6.31
Volume17,190 shs
Average Volume607,702 shs
Market Capitalization$234.09 million
P/E RatioN/A
Dividend YieldN/A
Beta1.47
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase II clinical trials to treat Parkinson's disease; and preclinical clinical trials to treat Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Its preclinical drug candidates include ANAVEX 3-71, a central nervous system (CNS)-penetrable mono-therapy to treat Alzheimer's and Parkinson's diseases; ANAVEX 1-41, a sigma-1 agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.
Read More
Anavex Life Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVXL
CUSIPN/A
Phone844-689-3939

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.39 per share

Profitability

Net Income$-26,300,000.00

Miscellaneous

Employees16
Market Cap$234.09 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive AVXL News and Ratings via Email

Sign-up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.

Anavex Life Sciences (NASDAQ:AVXL) Frequently Asked Questions

How has Anavex Life Sciences' stock been impacted by COVID-19 (Coronavirus)?

Anavex Life Sciences' stock was trading at $3.32 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AVXL stock has increased by 20.2% and is now trading at $3.99. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Anavex Life Sciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Anavex Life Sciences.

When is Anavex Life Sciences' next earnings date?

Anavex Life Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Anavex Life Sciences.

How were Anavex Life Sciences' earnings last quarter?

Anavex Life Sciences Corp (NASDAQ:AVXL) posted its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.14) by $0.02. View Anavex Life Sciences' earnings history.

What price target have analysts set for AVXL?

4 analysts have issued 1-year price targets for Anavex Life Sciences' stock. Their forecasts range from $10.00 to $16.00. On average, they anticipate Anavex Life Sciences' stock price to reach $12.67 in the next year. This suggests a possible upside of 217.5% from the stock's current price. View analysts' price targets for Anavex Life Sciences.

Has Anavex Life Sciences been receiving favorable news coverage?

Media coverage about AVXL stock has been trending somewhat positive this week, according to InfoTrie. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Anavex Life Sciences earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the company's share price in the near future. View the latest news aboutAnavex Life Sciences.

Who are some of Anavex Life Sciences' key competitors?

What other stocks do shareholders of Anavex Life Sciences own?

Who are Anavex Life Sciences' key executives?

Anavex Life Sciences' management team includes the following people:
  • Dr. Christopher U. Missling, Chairman, Pres, CEO & Sec. (Age 54, Pay $573.7k)
  • Ms. Sandra Boenisch CPA, CGA, Principal Financial Officer & Treasurer (Age 39, Pay $85.89k)
  • Mr. Stephan Toutain, Chief Operating Officer (Age 54)
  • Dr. Emmanuel O. Fadiran RPh, Ph.D., Sr. VP of Regulatory Affairs
  • Dr. Walter E. Kaufmann, Chief Medical Officer

What is Anavex Life Sciences' stock symbol?

Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL."

Who are Anavex Life Sciences' major shareholders?

Anavex Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.62%), State Street Corp (1.40%), Geode Capital Management LLC (1.22%), Russell Investments Group Ltd. (0.41%), Nuveen Asset Management LLC (0.36%) and Bank of New York Mellon Corp (0.27%). View institutional ownership trends for Anavex Life Sciences.

Which institutional investors are selling Anavex Life Sciences stock?

AVXL stock was sold by a variety of institutional investors in the last quarter, including Hikari Power Ltd, Morgan Stanley, UBS Group AG, AllSquare Wealth Management LLC, and Kessler Investment Group LLC. View insider buying and selling activity for Anavex Life Sciences.

Which institutional investors are buying Anavex Life Sciences stock?

AVXL stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Russell Investments Group Ltd., Geode Capital Management LLC, Nuveen Asset Management LLC, Thrivent Financial for Lutherans, Wells Fargo & Company MN, Alliancebernstein L.P., and AQR Capital Management LLC. View insider buying and selling activity for Anavex Life Sciences.

How do I buy shares of Anavex Life Sciences?

Shares of AVXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Anavex Life Sciences' stock price today?

One share of AVXL stock can currently be purchased for approximately $3.99.

How big of a company is Anavex Life Sciences?

Anavex Life Sciences has a market capitalization of $234.09 million. The biotechnology company earns $-26,300,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Anavex Life Sciences employs 16 workers across the globe.

What is Anavex Life Sciences' official website?

The official website for Anavex Life Sciences is www.anavex.com.

How can I contact Anavex Life Sciences?

Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 844-689-3939 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.